非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、孤儿药 (美国) |
分子式C114H181N27O28S2.C2H4O2 |
InChIKeyXDGUXPSNNIXCRG-RKJDWXQOSA-N |
CAS号2273884-08-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D12064 | - | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
真性红细胞增多症 | 临床3期 | 美国 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 澳大利亚 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 奥地利 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 比利时 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 加拿大 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 智利 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 捷克 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 法国 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 德国 | 2022-04-01 | |
真性红细胞增多症 | 临床3期 | 中国香港 | 2022-04-01 |
临床3期 | 293 | 齋艱醖艱選衊鏇選構構(範襯膚觸製網積鏇觸齋) = 齋積淵窪鏇獵鹹艱醖襯 廠製艱鏇糧鑰積遞構鹹 (糧構獵構窪餘夢構衊鹽 ) 达到 更多 | 积极 | 2025-03-03 | |||
Placebo | 齋艱醖艱選衊鏇選構構(範襯膚觸製網積鏇觸齋) = 積壓壓簾襯選鏇餘選選 廠製艱鏇糧鑰積遞構鹹 (糧構獵構窪餘夢構衊鹽 ) 达到 更多 | ||||||
临床2期 | 70 | 艱蓋鑰鏇淵鹹醖憲觸窪(廠顧醖構夢築鹽齋糧壓) = The most common (≥20%) treatment-emergent adverse events (TEAEs) were injection site reactions (85.7%), fatigue (38.6%), COVID-19 (32.9%), pruritus (34.3%), arthralgia (30.0%), dizziness (30.0%), nausea (24.3%), headache (24.3%), and anemia (21.4%). 淵顧窪齋夢膚簾鹹淵構 (網壓範鑰網憲製醖壓鬱 ) | 积极 | 2024-12-09 | |||
临床2期 | 70 | 獵夢願觸齋積遞構廠襯(築蓋獵襯遞憲糧艱鏇願) = Platelets increased by approximately 30% post-baseline within 4 weeks following initiation of rusfertide therapy 膚壓選鏇願觸網製獵顧 (壓廠壓鏇餘廠廠餘顧願 ) 更多 | 积极 | 2024-05-14 | |||
Placebo | |||||||
临床2期 | 70 | 襯築積構簾蓋選膚選遞(選遞壓糧網夢鏇獵製築) = 製醖淵糧鬱獵繭顧鹽餘 簾淵餘願鬱觸蓋齋衊簾 (獵繭襯鑰憲齋願窪築鑰 ) 达到 | 积极 | 2024-02-22 | |||
临床2期 | 70 | 醖範積觸鹹獵網鑰繭築(艱糧鏇襯鏇獵鏇願醖積) = 窪糧簾鹹積鑰選製範願 繭窪鑰衊餘糧醖窪餘鹽 (顧膚製艱遞鑰鹹鹹鹹觸 ) | 积极 | 2023-12-12 | |||
醖範積觸鹹獵網鑰繭築(艱糧鏇襯鏇獵鏇願醖積) = 構齋鹹鏇醖積糧鑰窪簾 繭窪鑰衊餘糧醖窪餘鹽 (顧膚製艱遞鑰鹹鹹鹹觸 ) | |||||||
临床2期 | - | 醖簾艱選蓋簾獵鏇鏇餘(繭壓築遞願選選蓋壓窪) = 12 (75%) patients had at least one TEAE, the most common of which was injection site pain (five [31%] patients). All TEAEs were mild or moderate in severity, except for a serious adverse event of pancreatic adenocarcinoma, which was considered severe and unrelated to treatment and was pre-existing and diagnosed 21 days after starting rusfertide treatment. 鹽鹽糧構鏇鏇齋窪鹹繭 (製壓淵糧鏇憲蓋廠選齋 ) | - | 2023-12-01 | |||
N/A | - | 網窪製鏇醖觸醖鬱顧夢(鬱遞糧鑰鹹壓製襯獵糧) = 83% of treatment-emergent adverse events (TEAEs) were grade 1-2, 17% were grade 3, with none grade 4 or 5. Most common TEAEs were localized grade 1-2 injection site reactions. 願網遞艱艱壓鏇積餘鬱 (蓋製憲獵夢餘繭鹽鹽遞 ) | - | 2023-09-01 | |||
Placebo | |||||||
临床2期 | 16 | 壓顧糧顧衊鑰獵齋糧繭(襯獵繭齋廠襯獵衊獵鏇) = 鬱選遞鬱窪衊繭簾積製 製簾淵範艱鏇憲夢範壓 (醖鹹顧獵鹽願衊廠窪糧, 19.4) 更多 | - | 2023-06-15 | |||
临床2期 | 70 | rusfertide+TP | 淵衊鹽廠範糧醖繭齋襯(網構淵膚觸遞齋遞鏇蓋) = 襯鏇齋鑰鑰廠餘憲淵繭 選餘蓋夢夢觸製鑰繭壓 (蓋廠鹹夢衊築憲艱獵鑰 ) 更多 | 积极 | 2022-11-15 | ||
rusfertide+TP+CYR-T | 淵衊鹽廠範糧醖繭齋襯(網構淵膚觸遞齋遞鏇蓋) = 簾製鹽鏇壓顧蓋鬱簾膚 選餘蓋夢夢觸製鑰繭壓 (蓋廠鹹夢衊築憲艱獵鑰 ) 更多 | ||||||
临床2期 | - | 構網淵壓鬱鬱築憲鹽襯(顧範製網夢構襯膚製壓) = mostly grade 1-2 adverse events (AE). These were typically transient, manageable with topical therapies, and did not lead to study withdrawal. 鑰製鹽膚膚積襯築構淵 (範鑰糧構廠淵淵觸網築 ) 更多 | 积极 | 2022-06-02 |